Navigation Links
Catalent Provides Commercial Manufacturing of Lexicon Pharmaceuticals' Orphan Drug XERMELO™ Following FDA Approval
Date:5/9/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently welcomed Lexicon Pharmaceuticals, Inc.’s announcement that its pioneering orphan drug, XERMELO™, has been approved by the U.S. Food and Drug Administration (FDA). Catalent has been working in partnership with Lexicon since 2007 to develop the drug formulation, and will be manufacturing XERMELO for commercial supply.

XERMELO (telotristat ethyl) 250 mg is a first-in-class orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

“We are pleased that the skill and expertise that our scientists have dedicated to this project for ten years has resulted in this pioneering treatment reaching the market,” commented Matthew Mollan, Catalent's General Manager at its Kansas City, Missouri site. “Catalent first partnered with Lexicon when the drug was in Phase I development, and continued to support its manufacture through to supplying launch products.”

"We are proud to have discovered this ground-breaking orphan drug, and our successful collaboration with Catalent means we are now able to make it available for the thousands of patients currently suffering from this condition,” added Lonnel Coats, Lexicon's president and chief executive officer.

Carcinoid syndrome is a rare condition that occurs in patients living with metastatic neuroendocrine tumors (mNETs) and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.

Catalent undertook development and manufacture of the drug at its 450,000-square-foot Kansas City facility, where the company provides a range of fully integrated support services, from formulation development and analytical testing, to clinical and commercial scale manufacturing and packaging of various oral dose forms.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2017/05/prweb14316592.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent to Launch Innovative Fish Oil Supplement Product at Vitafoods Europe
2. Challenges and Strategies to Automate Potency Assays to be Discussed by Catalent Expert at Upcoming CASSS Bioassays Symposium
3. Catalent Expands Kansas City Clinical Storage and Secondary Packaging Capabilities to Meet Growing Demand for Cold Chain Services
4. Catalent Wins Prestigious Clinical Supply Chain Excellence Award at BioPharma Asia Convention
5. Challenges and Innovation in Clinical Trial Supply to be Presented by Catalent Experts at Upcoming Conferences
6. Catalent to Host Workshop with Leading Biologics Experts on Advanced Protein Development and Delivery at Upcoming Drug Delivery Partnerships Conference
7. Innovative Strategies for the Development of Lipid-based Oral Medicines to be Presented by Catalent and Gattefossé at Forthcoming Workshop
8. Accelerated Biopharmaceutical Development through Strategic Analytical Partnerships to be Discussed by Catalent Expert at Upcoming WCBP Conference
9. Catalent to Develop Softgel Capsules for JOT’s Leading Orphan Disease Candidates
10. Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development
11. Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative: Helps Shape Better Supply Chain to Pharmaceutical and Healthcare Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... ... out your dear friend has cancer? , It’s hard to hear your doctor say the ... Once the shock wears off, the questions and fears can be overwhelming. , How should ... help? Words are failing me. I’m scared. I want to DO something. , We’ve talked ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... services to dental groups in the United States, today announced the grand opening ... Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, and ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... improve outcomes for patients with advanced heart failure, today announced that the company ... the amount of $555,358 from the National Heart, Lung, and Blood Institute of ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free events being ... helping the specialty-diet community connect with great, gluten-free brands. At the Online ... chat with brands & watch over 50 educational classes... all online from the ...
(Date:8/27/2020)... ... August 27, 2020 , ... The team at ... aesthetic and wellness retreat. The practice is centered on results and providing the ... , Designed to be a sanctuary for total body renewal and aesthetic ...
Breaking Medicine News(10 mins):
(Date:9/2/2020)... , ... September 02, 2020 , ... ... Raman technology, will moderate a roundtable discussion among industry professionals about successes and ... be hosted by American Pharmaceutical Review and will take place on ...
(Date:9/1/2020)... ... September 01, 2020 , ... Neil Oberfeld of global law ... the Board of Trustees and committee chair of the Governance Committee for Mile ... nonprofit organization that fights for the education, health, and financial stability of residents ...
(Date:8/31/2020)... YORK (PRWEB) , ... August 31, 2020 , ... If you live in New York ... The real estate part makes sense, it’s the law of supply and demand, but are ... Center has a significant percentage of their patients that make the four-hour trip to ...
Breaking Medicine Technology: